|
G |
Alb |
albumin |
multiple interactions |
ISO |
allicin inhibits the reaction [Acetaminophen results in decreased expression of ALB protein] |
CTD |
PMID:32040233 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
allicin inhibits the reaction [arsenic trioxide results in increased expression of BAX protein] |
CTD |
PMID:27561292 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
allicin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] |
CTD |
PMID:32040233 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
allicin inhibits the reaction [arsenic trioxide results in decreased expression of BCL2L1 protein] |
CTD |
PMID:27561292 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
allicin inhibits the reaction [Acetaminophen results in increased expression of CASP1 protein] |
CTD |
PMID:32040233 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
allicin inhibits the reaction [Acetaminophen results in increased expression of GPT protein] |
CTD |
PMID:32040233 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
allicin inhibits the reaction [arsenic trioxide results in decreased expression of HMOX1 protein] |
CTD |
PMID:27561292 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
allicin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12723939 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
allicin inhibits the reaction [IL1B protein affects the localization of RELA protein]; IL1B protein promotes the reaction [allicin results in increased phosphorylation of MAPK1 protein]; IL1B protein promotes the reaction [allicin results in increased phosphorylation of MAPK3 protein] allicin inhibits the reaction [Acetaminophen results in increased expression of IL1B protein] allicin results in increased expression of IL1B mRNA [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]; [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; [allicin co-treated with Sulfasalazine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]; [allicin co-treated with Sulfasalazine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; allicin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]; allicin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein] |
CTD |
PMID:25729217 PMID:32040233 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
[allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased secretion of IL4 protein] |
CTD |
PMID:25729217 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Klf9 |
KLF transcription factor 9 |
multiple interactions |
ISO |
allicin inhibits the reaction [arsenic trioxide results in decreased expression of KLF9 protein] |
CTD |
PMID:27561292 |
|
NCBI chr 1:220,700,108...220,725,029
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
allicin results in increased phosphorylation of MAPK1 protein IL1B protein promotes the reaction [allicin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:25729217 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
IL1B protein promotes the reaction [allicin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25729217 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
allicin inhibits the reaction [arsenic trioxide results in decreased expression of NFE2L2 protein] |
CTD |
PMID:27561292 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
allicin inhibits the reaction [Acetaminophen results in increased expression of NLRP3 protein] |
CTD |
PMID:32040233 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
allicin inhibits the reaction [arsenic trioxide results in decreased expression of NQO1 protein] |
CTD |
PMID:27561292 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
allicin inhibits the reaction [arsenic trioxide results in increased expression of RELA protein]; allicin inhibits the reaction [IL1B protein affects the localization of RELA protein] |
CTD |
PMID:25729217 PMID:27561292 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
allicin inhibits the reaction [TNF protein results in increased abundance of Hydrogen Peroxide]; allicin inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; allicin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; [allicin co-treated with Sulfasalazine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; allicin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] |
CTD |
PMID:12723939 PMID:25729217 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity multiple interactions |
EXP ISO |
allicin results in increased activity of TRPA1 protein [allicin binds to and results in increased activity of TRPA1 protein] which results in increased transport of Calcium; allicin binds to and results in increased activity of TRPA1 protein |
CTD |
PMID:17684094 PMID:17825279 PMID:20086034 |
|
NCBI chr 5:4,379,999...4,433,243
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
affects response to substance increases response to substance |
ISO |
TRPV1 protein affects the susceptibility to allicin TRPV1 protein mutant form results in increased susceptibility to allicin |
CTD |
PMID:17110039 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Santonin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
[Santonin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
berberine increases expression of abca1 protein in mouse liver and human hepatocytes |
RGD |
PMID:29505790 |
RGD:19165131 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Berberine results in increased expression of ABCB1A mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
Berberine results in increased expression of ABCB1B mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acan |
aggrecan |
decreases expression |
ISO |
Berberine results in decreased expression of ACAN mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA] Berberine results in decreased activity of ACHE protein |
CTD |
PMID:29170048 PMID:33844597 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
EXP |
Berberine results in decreased expression of ACTA2 protein |
CTD |
PMID:17973934 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
EXP ISO |
Berberine results in increased activity of AHR protein |
CTD |
PMID:16046213 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23954465 PMID:30138605 PMID:33325633 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] |
CTD |
PMID:30138605 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Berberine results in decreased expression of AURKB mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Aurkc |
aurora kinase C |
increases expression |
ISO |
Berberine results in increased expression of AURKC mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:66,843,653...66,864,348
Ensembl chr 1:66,843,653...66,864,386
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:36070022 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BBC3 mRNA [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression increases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 PMID:26712469 PMID:30138605 PMID:36070022 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
Berberine results in decreased expression of BCL2L1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA Berberine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein] |
CTD |
PMID:26478571 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects binding |
ISO |
Berberine binds to BIRC5 promoter |
CTD |
PMID:17968851 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3 protein Berberine results in increased expression of BNIP3 protein |
CTD |
PMID:36070022 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BNIP3L protein [Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO EXP |
[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine increases activity of CASP3 protein in colon epithelial cells Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA |
CTD RGD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:36070022 PMID:29564000 More...
|
RGD:152995489 |
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Berberine results in increased activity of CASP8 protein |
CTD |
PMID:20656010 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Berberine results in increased cleavage of CASP9 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein |
CTD |
PMID:16505103 PMID:26712469 PMID:30138605 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein] |
CTD |
PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 PMID:35121005 PMID:35691465 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein] |
CTD |
PMID:16391493 PMID:35691465 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND1 protein |
CTD |
PMID:16505103 PMID:33325633 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCNE1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccnt1 |
cyclin T1 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 7:129,687,146...129,718,082
Ensembl chr 7:129,691,209...129,717,871
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CD36 mRNA Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] |
CTD |
PMID:28038998 PMID:29408570 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDH2 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK4 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK6 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Berberine results in increased expression of CDKN1A protein |
CTD |
PMID:16505103 PMID:23747414 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Berberine results in increased expression of CDKN1B protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Berberine results in increased expression of CDKN1C mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects phosphorylation multiple interactions increases expression |
ISO |
Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CEBPB mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
Berberine results in increased expression of CHEK1 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
Berberine results in increased expression of CHEK2 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL10A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL1A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
Berberine results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] |
CTD |
PMID:35121005 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Berberine results in increased expression of CREBBP mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
multiple interactions decreases cleavage |
ISO |
GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSD protein] |
CTD |
PMID:36070022 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
decreases cleavage multiple interactions |
ISO |
Berberine results in decreased cleavage of CTSL protein Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein] |
CTD |
PMID:36070022 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
Berberine affects the localization of CYCS protein [Berberine co-treated with Cisplatin] results in increased expression of CYCS protein |
CTD |
PMID:16505103 PMID:36070022 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression multiple interactions |
ISO EXP |
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16046213 PMID:22342832 PMID:24583342 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] Berberine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B9 mRNA]; Berberine promotes the reaction [Streptozocin results in increased expression of CYP2B9 mRNA] Berberine results in increased expression of CYP2B9 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:22342832 PMID:25455889 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression multiple interactions decreases activity |
EXP ISO |
Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] |
CTD |
PMID:21524698 PMID:30086269 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dzip3 |
DAZ interacting zinc finger protein 3 |
increases expression |
ISO |
Berberine results in increased expression of DZIP3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:51,823,235...51,893,353
Ensembl chr11:51,823,231...51,893,353
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Berberine results in decreased expression of EGFR protein |
CTD |
PMID:33325633 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Berberine results in increased expression of EP300 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein |
CTD |
PMID:33325633 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression multiple interactions increases expression |
ISO |
Berberine results in decreased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA] |
CTD |
PMID:26478571 PMID:29408570 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein |
CTD |
PMID:20564506 PMID:20656010 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein |
CTD |
PMID:20656010 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:26712469 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:26712469 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fundc1 |
FUN14 domain containing 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of FUNDC1 protein [Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:5,083,635...5,100,293
Ensembl chr X:5,083,617...5,100,284
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf5 |
growth differentiation factor 5 |
decreases expression |
ISO |
Berberine results in decreased expression of GDF5 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 3:144,454,306...144,458,757
Ensembl chr 3:144,454,338...144,458,612
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] |
CTD |
PMID:24751971 PMID:25455889 PMID:30138605 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA] |
CTD |
PMID:24751971 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:20462044 PMID:23954465 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:24751971 PMID:25600690 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
H2ac12 |
H2A clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,486,315...42,486,880
Ensembl chr17:42,486,415...42,486,941
|
|
G |
H2ac18 |
H2A clustered histone 18 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC18 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,808,398...183,808,922
|
|
G |
H2ac25 |
H2A clustered histone 25 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC25 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874
|
|
G |
H2ac4 |
H2A clustered histone 4 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,799,953...42,800,345
Ensembl chr17:42,799,652...42,800,381
|
|
G |
H2ax |
H2A.X variant histone |
increases expression decreases expression multiple interactions |
ISO |
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] |
CTD |
PMID:23363784 PMID:23747414 PMID:27311644 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,485,746...42,486,126
|
|
G |
H2bc6 |
H2B clustered histone 6 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,520,767...41,521,240
|
|
G |
H2bc8 |
H2B clustered histone 8 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,708,646...42,709,435
|
|
G |
H2bc9 |
H2B clustered histone 9 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,470,593...42,478,605
|
|
G |
H3c1 |
H3 clustered histone 1 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,367,824...41,368,902
Ensembl chr17:41,368,386...41,368,856
|
|
G |
H3f3a |
H3.3 histone A |
decreases expression |
ISO |
Berberine results in decreased expression of H3-3A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:92,533,294...92,544,903
Ensembl chr13:92,533,298...92,544,908
|
|
G |
H3f4 |
H3.4 histone, cluster member |
decreases expression |
ISO |
Berberine results in decreased expression of H3-4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,740,797...43,741,207
|
|
G |
H4c3 |
H4 clustered histone 3 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C3 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Hat1 |
histone acetyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of HAT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac5 |
histone deacetylase 5 |
increases expression |
ISO |
Berberine results in increased expression of HDAC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hdac8 |
histone deacetylase 8 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hdac9 |
histone deacetylase 9 |
decreases expression increases expression |
ISO |
Berberine results in decreased expression of HDAC9 mRNA Berberine results in increased expression of HDAC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] |
CTD |
PMID:29408570 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,384,521...41,385,018
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hist1h2bq |
histone cluster 1 H2B family member Q |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153
|
|
G |
Hist1h3b |
histone cluster 1, H3b |
decreases expression |
ISO |
Berberine results in decreased expression of H3C12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,722,805...42,723,925
Ensembl chr17:42,723,450...42,723,911
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
decreases expression |
ISO |
Berberine results in decreased expression of H4C9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,780,449...183,783,030
|
|
G |
Hist2h4 |
histone cluster 2, H4 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,831,601...183,831,996
Ensembl chr 2:183,825,994...183,832,048
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Berberine results in increased expression of HMOX1 protein Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein] |
CTD |
PMID:23954465 PMID:35121005 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein] |
CTD |
PMID:18563319 PMID:25455889 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Berberine results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Berberine results in increased expression of IGF1R protein |
CTD |
PMID:23954465 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA Berberine results in increased expression of IL10 mRNA |
CTD |
PMID:21867779 PMID:30138605 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] |
CTD |
PMID:16391493 PMID:29170048 PMID:30138605 PMID:35121005 PMID:35691465 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Berberine results in increased expression of IL2 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein] |
CTD |
PMID:30240693 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein] |
CTD |
PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 PMID:35121005 PMID:35691465 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga1 |
integrin subunit alpha 1 |
increases expression |
ISO |
Berberine results in increased expression of ITGA1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
|
|
G |
Itgb4 |
integrin subunit beta 4 |
increases expression |
ISO |
berberine increases expression of ITGB4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects localization multiple interactions |
EXP |
Berberine affects the localization of JUN protein arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein] |
CTD |
PMID:18294404 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
EXP |
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm1a |
lysine demethylase 1A |
increases expression |
ISO |
Berberine results in increased expression of KDM1A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm4a |
lysine demethylase 4A |
increases expression |
ISO |
Berberine results in increased expression of KDM4A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501
|
|
G |
Kdm5b |
lysine demethylase 5B |
increases expression |
ISO |
Berberine results in increased expression of KDM5B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872
|
|
G |
Kdm6a |
lysine demethylase 6A |
increases expression |
ISO |
Berberine results in increased expression of KDM6A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062
|
|
G |
Kdm6b |
lysine demethylase 6B |
increases expression |
ISO |
Berberine results in increased expression of KDM6B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:54,120,716...54,142,212
Ensembl chr10:54,121,848...54,130,794
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
increases expression |
ISO |
Berberine results in increased expression of KMT5A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:32,139,353...32,167,777
Ensembl chr12:32,139,178...32,162,711
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] |
CTD |
PMID:18640378 PMID:20564506 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
LOC103690190 |
histone H2A type 1-E |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,707,863...42,708,420
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
EXP |
Berberine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:18294404 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA] |
CTD |
PMID:18294404 PMID:20462044 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36070022 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mir19a |
microRNA 19a |
decreases expression |
ISO |
Berberine results in decreased expression of MIR19A mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993
|
|
G |
Mir21 |
microRNA 21 |
decreases expression |
ISO |
berberine decreases expression of MIR21 RNA in colon epithelial cell |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir92a1 |
microRNA 92a-1 |
decreases expression |
ISO |
Berberine results in decreased expression of MIR92A1 mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,181,336...92,181,413
Ensembl chr15:92,181,336...92,181,413
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Berberine results in increased expression of MMP13 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein] |
CTD |
PMID:18294404 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] |
CTD |
PMID:18294404 PMID:33325633 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions |
ISO |
Berberine results in decreased activity of MMP9 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] |
CTD |
PMID:21963898 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein] |
CTD |
PMID:25455889 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects localization |
EXP |
arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein] |
CTD |
PMID:18294404 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein] |
CTD |
PMID:26712469 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein] |
CTD |
PMID:36070022 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr13:64,955,502...64,986,289
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression increases activity multiple interactions |
ISO EXP |
Berberine results in increased expression of NFE2L2 protein Berberine results in increased activity of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23523906 PMID:23954465 PMID:30818834 PMID:35121005 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:21963898 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23954465 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:21095217 PMID:23523906 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
IEP EXP |
Berberine reverses reaction [Carbon tetrachloride decreases Nqo1 mRNA in liver] Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA] |
CTD RGD |
PMID:35121005 PMID:31432116 |
RGD:25823187 |
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21524698 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Berberine results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
decreases expression |
ISO |
Berberine results in decreased expression of NSD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:76,833,194...76,911,304
Ensembl chr14:76,835,637...76,913,641
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein] |
CTD |
PMID:18294404 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Omd |
osteomodulin |
increases expression |
ISO |
Berberine results in increased expression of OMD mRNA |
CTD |
PMID:26478571 |
|
NCBI chr17:15,060,217...15,068,441
Ensembl chr17:15,060,217...15,068,441
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:21320518 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein] |
CTD |
PMID:16505103 PMID:26712469 PMID:36070022 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression |
ISO |
Berberine increases expression of PDCD4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases response to substance increases expression decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] PPARG mRNA results in increased susceptibility to Berberine Berberine results in increased expression of PPARG mRNA Berberine results in decreased expression of PPARG mRNA |
CTD |
PMID:20564506 PMID:26478571 PMID:29408570 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prg4 |
proteoglycan 4 |
decreases expression |
ISO |
Berberine results in decreased expression of PRG4 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
ISO |
Berberine results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:28298333 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein |
CTD |
PMID:18294404 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions decreases activity |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein |
CTD |
PMID:18294404 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of PRMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Prmt2 |
protein arginine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of PRMT2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:12,394,748...12,420,643
Ensembl chr20:12,394,798...12,420,643
|
|
G |
Prmt5 |
protein arginine methyltransferase 5 |
increases expression |
ISO |
Berberine results in increased expression of PRMT5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:27,968,893...27,978,291
Ensembl chr15:27,968,910...27,978,296
|
|
G |
Prmt6 |
protein arginine methyltransferase 6 |
increases expression |
ISO |
Berberine results in increased expression of PRMT6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:197,927,750...197,932,980
Ensembl chr 2:197,927,220...197,933,648
|
|
G |
Prmt7 |
protein arginine methyltransferase 7 |
increases expression |
ISO |
Berberine results in increased expression of PRMT7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:34,110,724...34,161,531
Ensembl chr19:34,110,747...34,162,577
|
|
G |
Prmt8 |
protein arginine methyltransferase 8 |
increases expression |
ISO |
Berberine results in increased expression of PRMT8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:160,535,813...160,618,193
Ensembl chr 4:160,535,813...160,617,930
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein |
CTD |
PMID:29408570 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] |
CTD |
PMID:21095217 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac2 |
Rac family small GTPase 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein |
CTD |
PMID:36070022 |
|
NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] |
CTD |
PMID:23523906 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
RGD1562378 |
histone H4 variant H4-v.1 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C14 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Rln1 |
relaxin 1 |
affects binding increases expression multiple interactions |
EXP |
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA |
CTD |
PMID:22363579 |
|
NCBI chr 1:227,079,960...227,082,960
Ensembl chr 1:227,079,966...227,082,882
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26478571 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Setd1b |
SET domain containing 1B, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD1B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934
|
|
G |
Setd2 |
SET domain containing 2, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:110,511,808...110,597,489
Ensembl chr 8:110,511,772...110,597,489
|
|
G |
Setd3 |
SET domain containing 3, actin histidine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:127,023,058...127,090,020
Ensembl chr 6:127,023,058...127,090,008
|
|
G |
Setd5 |
SET domain containing 5 |
increases expression |
ISO |
Berberine results in increased expression of SETD5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:146,217,172...146,294,896
Ensembl chr 4:146,217,180...146,294,894
|
|
G |
Setd6 |
SET domain containing 6, protein lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453
|
|
G |
Setd7 |
SET domain containing 7, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:135,562,683...135,605,468
Ensembl chr 2:135,562,683...135,605,468
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of SETDB1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Setdb2 |
SET domain bifurcated histone lysine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of SETDB2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:33,553,657...33,606,586
Ensembl chr15:33,453,952...33,606,470
|
|
G |
Si |
sucrase-isomaltase |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein] |
CTD |
PMID:26712469 PMID:35121005 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:26712469 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 PMID:27311644 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
decreases expression |
ISO |
Berberine results in decreased expression of SLC27A5 mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc6a19 |
solute carrier family 6 member 19 |
multiple interactions |
EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein] |
CTD |
PMID:21073932 |
|
NCBI chr 1:29,586,205...29,604,960
Ensembl chr 1:29,586,195...29,604,962
|
|
G |
Smyd3 |
SET and MYND domain containing 3 |
affects expression |
ISO |
Berberine affects the expression of SMYD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] |
CTD |
PMID:21095217 PMID:22775417 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:22775417 PMID:24751971 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Berberine results in decreased expression of SOX9 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Berberine results in increased expression of SP7 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
Berberine results in increased expression of SPARC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Berberine results in increased expression of SQSTM1 protein |
CTD |
PMID:36070022 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
Berberine results in decreased activity of TERT protein |
CTD |
PMID:25265580 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression multiple interactions |
EXP |
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] |
CTD |
PMID:17973934 PMID:23523906 PMID:30138605 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein] |
CTD |
PMID:21963898 PMID:30240693 PMID:35121005 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO EXP |
Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 PMID:25600690 PMID:28533128 PMID:29170048 PMID:30240693 PMID:35121005 PMID:35691465 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Berberine results in decreased activity of TOP1 protein |
CTD |
PMID:23747414 |
|
NCBI chr 3:149,293,658...149,375,405
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions affects response to substance |
ISO |
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine |
CTD |
PMID:23747414 |
|
NCBI chr10:83,946,186...83,975,694
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein |
CTD |
PMID:20656010 PMID:26712469 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Berberine results in increased expression of TRAF1 protein |
CTD |
PMID:20656010 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Tstd1 |
thiosulfate sulfurtransferase like domain containing 1 |
increases expression |
ISO |
Berberine results in increased expression of TSTD1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:83,853,421...83,854,875
Ensembl chr13:83,822,035...83,854,885
|
|
G |
Ube2a |
ubiquitin-conjugating enzyme E2A |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:116,114,339...116,125,076
Ensembl chr X:116,113,875...116,125,070
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA] |
CTD |
PMID:28533128 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Berberine results in decreased expression of VEGFA protein |
CTD |
PMID:33325633 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression |
ISO |
Berberine results in increased expression of VEGFC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr16:37,712,408...37,827,657
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP |
[propiconazole co-treated with carvacrol] results in decreased activity of ACHE protein carvacrol results in decreased activity of ACHE protein |
CTD |
PMID:29852196 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
carvacrol inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]; carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]] |
CTD |
PMID:29071762 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO |
[4-cymene co-treated with gamma-terpinene co-treated with Thymol co-treated with carvacrol] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; [4-cymene co-treated with gamma-terpinene co-treated with Thymol co-treated with carvacrol] results in increased activity of AHR protein; carvacrol inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] carvacrol results in increased activity of AHR protein |
CTD |
PMID:29191726 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO EXP |
carvacrol results in increased activity of CASP3 protein carvacrol inhibits the reaction [Poloxamer results in increased expression of CASP3 protein]; carvacrol inhibits the reaction [propiconazole results in increased expression of CASP3 protein]; carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]] |
CTD |
PMID:23146755 PMID:29071762 PMID:29852196 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
carvacrol inhibits the reaction [Poloxamer results in decreased activity of CAT protein]; carvacrol inhibits the reaction [propiconazole results in decreased activity of CAT protein]; carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]] carvacrol inhibits the reaction [Diethylhexyl Phthalate results in increased activity of CAT protein] carvacrol inhibits the reaction [Benzo(a)pyrene results in decreased activity of CAT protein] |
CTD |
PMID:29019276 PMID:29071762 PMID:29852196 PMID:35521929 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
EXP |
carvacrol inhibits the reaction [Poloxamer results in increased secretion of CKM protein]; carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein] |
CTD |
PMID:29071762 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Cryz |
crystallin zeta |
multiple interactions |
ISO |
carvacrol inhibits the reaction [Benzo(a)pyrene results in decreased activity of CRYZ protein] |
CTD |
PMID:29019276 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [irinotecan results in increased expression of CXCL1 protein]]; carvacrol inhibits the reaction [irinotecan results in increased expression of CXCL1 protein] |
CTD |
PMID:27838229 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
carvacrol results in increased expression of CYP1A1 mRNA carvacrol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:29191726 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Egfr |
epidermal growth factor receptor |
increases phosphorylation multiple interactions |
ISO |
carvacrol results in increased phosphorylation of EGFR protein KN 93 inhibits the reaction [carvacrol results in increased phosphorylation of EGFR protein]; TRPV3 protein affects the reaction [carvacrol results in increased phosphorylation of EGFR protein] |
CTD |
PMID:32535744 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
carvacrol inhibits the reaction [propiconazole results in increased expression of GFAP protein] |
CTD |
PMID:29852196 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Htr3a |
5-hydroxytryptamine receptor 3A |
increases activity |
ISO |
carvacrol results in increased activity of HTR3A protein |
CTD |
PMID:26456648 |
|
NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [irinotecan results in increased expression of IL1B protein]]; carvacrol inhibits the reaction [irinotecan results in increased expression of IL1B protein] |
CTD |
PMID:27838229 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
carvacrol inhibits the reaction [Poloxamer results in increased secretion of LEP protein] |
CTD |
PMID:29071762 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mb |
myoglobin |
multiple interactions |
EXP |
carvacrol inhibits the reaction [Poloxamer results in increased secretion of MB protein] |
CTD |
PMID:29071762 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [irinotecan results in increased activity of MPO protein]]; carvacrol inhibits the reaction [irinotecan results in increased activity of MPO protein] |
CTD |
PMID:27838229 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
carvacrol inhibits the reaction [irinotecan results in increased expression of NFKB1 protein] |
CTD |
PMID:27838229 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
carvacrol inhibits the reaction [Benzo(a)pyrene results in increased expression of NOS2 protein] |
CTD |
PMID:29019276 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions increases phosphorylation |
ISO |
Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of PIK3CA protein]; TRPV3 protein affects the reaction [carvacrol results in increased phosphorylation of PIK3CA protein] |
CTD |
PMID:32535744 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
carvacrol inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein]; carvacrol inhibits the reaction [Irinotecan results in increased expression of PTGS2 protein] carvacrol inhibits the reaction [propiconazole results in increased expression of PTGS2 protein] |
CTD |
PMID:27838229 PMID:29019276 PMID:29852196 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases phosphorylation |
ISO |
Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of RELA protein]; TRPV3 protein affects the reaction [carvacrol results in increased phosphorylation of RELA protein] |
CTD |
PMID:32535744 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tgfa |
transforming growth factor alpha |
increases secretion multiple interactions |
ISO |
carvacrol results in increased secretion of TGFA protein KN 93 inhibits the reaction [carvacrol results in increased secretion of TGFA protein] |
CTD |
PMID:32535744 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide inhibits the reaction [carvacrol inhibits the reaction [irinotecan results in increased expression of TNF protein]]; carvacrol inhibits the reaction [irinotecan results in increased expression of TNF protein] |
CTD |
PMID:27838229 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity |
EXP ISO |
carvacrol results in increased activity of TRPA1 protein |
CTD |
PMID:16617338 PMID:22935519 |
|
NCBI chr 5:4,379,999...4,433,243
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
increases activity affects response to substance multiple interactions increases response to substance |
ISO EXP |
carvacrol results in increased activity of TRPV3 protein TRPV3 protein affects the susceptibility to carvacrol TRPV3 protein affects the reaction [carvacrol results in increased phosphorylation of EGFR protein]; TRPV3 protein affects the reaction [carvacrol results in increased phosphorylation of PIK3CA protein]; TRPV3 protein affects the reaction [carvacrol results in increased phosphorylation of RELA protein] TRPV3 protein results in increased susceptibility to carvacrol [carvacrol binds to and results in increased activity of TRPV3 protein] which results in increased transport of Calcium; [carvacrol results in increased activity of TRPV3 protein] which results in increased transport of Calcium; carvacrol binds to and results in increased activity of TRPV3 protein; Ruthenium Red inhibits the reaction [[carvacrol binds to and results in increased activity of TRPV3 protein] which results in increased transport of Calcium] |
CTD |
PMID:16617338 PMID:20086034 PMID:29658714 PMID:32535744 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
carvacrol inhibits the reaction [Benzo(a)pyrene results in increased activity of XDH protein] |
CTD |
PMID:29019276 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
[carvone co-treated with limonene] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]; carvone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:29191726 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
carvone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] carvone results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29191726 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
carvone promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
carvone promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
carvone promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,376,805...26,463,680
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gna15 |
G protein subunit alpha 15 |
multiple interactions increases response to substance |
ISO |
[GNA15 protein results in increased susceptibility to carvone] which results in increased activity of OR1J21 protein |
CTD |
PMID:9875846 |
|
NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
increases expression increases secretion |
ISO |
carvone results in increased expression of GNRH1 mRNA carvone results in increased secretion of GNRH1 protein |
CTD |
PMID:10566683 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases response to substance |
ISO |
POR protein results in increased susceptibility to carvone analog |
CTD |
PMID:21376747 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Rhoa |
ras homolog family member A |
increases expression multiple interactions |
ISO |
carvone results in increased expression of RHOA protein Mevalonic Acid affects the reaction [carvone results in increased expression of RHOA protein] |
CTD |
PMID:12671036 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions increases expression |
ISO |
Mevalonic Acid affects the reaction [carvone results in increased expression of RHOB protein] |
CTD |
PMID:12671036 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
dihydrosanguinarine results in increased activity of CASP3 protein |
CTD |
PMID:19346183 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
dihydrosanguinarine results in increased activity of CASP9 protein |
CTD |
PMID:19346183 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases chemical synthesis |
EXP |
NQO1 protein results in increased chemical synthesis of dihydrosanguinarine |
CTD |
PMID:24300172 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
osthol results in increased expression of ACSL1 mRNA |
CTD |
PMID:19682441 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
osthol results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:31870840 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
osthol results in increased expression of BAK1 protein |
CTD |
PMID:29319219 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
osthol results in increased expression of BAX protein |
CTD |
PMID:29319219 PMID:31870840 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
osthol results in decreased expression of BCL2 protein |
CTD |
PMID:29319219 PMID:31870840 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
osthol results in increased expression of BCL2L11 protein alternative form |
CTD |
PMID:29319219 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
osthol results in increased expression of BID protein modified form |
CTD |
PMID:29319219 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
osthol results in decreased expression of BIRC5 protein |
CTD |
PMID:31870840 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
osthol results in increased cleavage of CASP3 protein |
CTD |
PMID:29319219 PMID:31870840 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
osthol results in increased cleavage of CASP8 protein |
CTD |
PMID:29319219 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
osthol results in increased cleavage of CASP9 protein |
CTD |
PMID:29319219 PMID:31870840 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
osthol results in decreased expression of CCNB1 protein |
CTD |
PMID:31870840 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
osthol results in decreased expression of CDK1 protein |
CTD |
PMID:31870840 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
osthol results in increased expression of CEBPA mRNA |
CTD |
PMID:19682441 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
osthol results in increased expression of CPT1A mRNA |
CTD |
PMID:19682441 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
osthol results in increased expression of FABP4 mRNA |
CTD |
PMID:19682441 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
osthol results in increased expression of FADD protein |
CTD |
PMID:29319219 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
osthol results in increased expression of FAS protein |
CTD |
PMID:29319219 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
osthol results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:29319219 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
osthol results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:29319219 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
osthol results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:29319219 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
osthol results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:29319219 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
osthol results in decreased expression of MKI67 protein |
CTD |
PMID:31870840 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity |
ISO |
osthol results in decreased activity of MMP2 protein |
CTD |
PMID:22503731 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
osthol inhibits the reaction [RELA protein binds to MMP9 promoter]; osthol results in decreased activity of and results in decreased expression of MMP9 protein osthol results in decreased expression of MMP9 mRNA |
CTD |
PMID:22503731 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases degradation decreases phosphorylation |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [osthol results in decreased phosphorylation of and results in decreased degradation of NFKBIA protein] osthol results in decreased degradation of NFKBIA protein osthol results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:22503731 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage decreases expression multiple interactions |
ISO |
osthol results in increased cleavage of PARP1 protein osthol results in decreased expression of PARP1 protein osthol results in decreased expression of and results in increased cleavage of PARP1 protein |
CTD |
PMID:29319219 PMID:31870840 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
ISO |
osthol results in increased expression of PPARA mRNA; osthol results in increased expression of PPARA protein osthol inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA] |
CTD |
PMID:19682441 PMID:21854795 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
ISO |
osthol results in increased expression of PPARG mRNA; osthol results in increased expression of PPARG protein osthol inhibits the reaction [Isoproterenol results in decreased expression of PPARG mRNA] |
CTD |
PMID:19682441 PMID:21854795 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
osthol results in increased expression of PTEN protein |
CTD |
PMID:31870840 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
osthol inhibits the reaction [Isoproterenol results in increased expression of RELA protein] osthol affects the localization of RELA protein osthol inhibits the reaction [RELA protein binds to MMP9 promoter] |
CTD |
PMID:21854795 PMID:22503731 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases expression |
ISO |
osthol results in increased expression of RIPK1 protein |
CTD |
PMID:29319219 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
[platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; [platycodin D co-treated with osthol] results in decreased expression of SMAD2 mRNA; [platycodin D co-treated with osthol] results in decreased expression of SMAD2 protein |
CTD |
PMID:23603464 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
[platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; [platycodin D co-treated with osthol] results in decreased expression of SMAD3 mRNA; [platycodin D co-treated with osthol] results in decreased expression of SMAD3 protein |
CTD |
PMID:23603464 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad4 |
SMAD family member 4 |
multiple interactions |
ISO |
[platycodin D co-treated with osthol] results in decreased expression of SMAD4 mRNA; [platycodin D co-treated with osthol] results in decreased expression of SMAD4 protein |
CTD |
PMID:23603464 |
|
NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
osthol inhibits the reaction [Isoproterenol results in increased expression of TGFB1 mRNA]; osthol inhibits the reaction [Isoproterenol results in increased expression of TGFB1 protein] [platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; [platycodin D co-treated with osthol] inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:21854795 PMID:23603464 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
ISO |
[platycodin D co-treated with osthol] results in decreased expression of TGFBR2 mRNA; [platycodin D co-treated with osthol] results in decreased expression of TGFBR2 protein |
CTD |
PMID:23603464 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
osthol results in increased expression of TNFRSF1A protein |
CTD |
PMID:29319219 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
increases expression |
ISO |
osthol results in increased expression of TNFRSF1B protein |
CTD |
PMID:29319219 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
sanguinarine promotes the reaction [AHR protein binds to ARNT protein]; sanguinarine results in increased activity of and affects the localization of AHR protein; sanguinarine results in increased localization of and results in increased activity of AHR protein |
CTD |
PMID:15993743 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
sanguinarine promotes the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:15993743 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
sanguinarine results in increased expression of BAX protein sanguinarine results in increased expression of BAX mRNA; sanguinarine results in increased expression of BAX protein NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX protein] |
CTD |
PMID:22215411 PMID:24300172 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BBC3 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
sanguinarine results in decreased expression of BCL2 protein sanguinarine results in decreased expression of BCL2 mRNA; sanguinarine results in decreased expression of BCL2 protein NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 protein] [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in decreased expression of BCL2 protein |
CTD |
PMID:22215411 PMID:23660334 PMID:24300172 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l14 |
Bcl2-like 14 |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BCL2L14 mRNA sanguinarine results in increased expression of BCL2L14 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage |
ISO |
[Acetylcysteine results in decreased abundance of Reactive Oxygen Species] inhibits the reaction [sanguinarine results in increased cleavage of BID protein] |
CTD |
PMID:23660334 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BIK mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
[sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in decreased expression of BIRC2 protein |
CTD |
PMID:23660334 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of BNIP3L mRNA |
CTD |
PMID:24345465 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Card6 |
caspase recruitment domain family, member 6 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of CARD6 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 2:54,194,343...54,206,902
Ensembl chr 2:54,195,739...54,206,846
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of CASP1 mRNA sanguinarine results in increased expression of CASP1 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions increases activity |
ISO |
sanguinarine results in decreased expression of CASP3 protein alternative form [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine co-treated with arsenic trioxide] results in increased activity of CASP3 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in increased activity of CASP3 protein sanguinarine results in increased activity of CASP3 protein |
CTD |
PMID:19135517 PMID:19346183 PMID:20150630 PMID:22215411 PMID:23660334 PMID:24345465 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of CASP4 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO |
sanguinarine results in increased activity of CASP8 protein [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sanguinarine co-treated with arsenic trioxide] results in increased activity of CASP8 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein |
CTD |
PMID:19346183 PMID:23660334 PMID:24345465 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
decreases expression multiple interactions increases activity |
ISO |
sanguinarine results in decreased expression of CASP9 protein alternative form [sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in increased activity of CASP9 protein sanguinarine results in increased activity of CASP9 protein |
CTD |
PMID:19135517 PMID:19346183 PMID:22215411 PMID:23660334 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of CAT protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of CAT protein |
CTD |
PMID:20691676 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
sanguinarine results in increased expression of CDKN1A protein |
CTD |
PMID:15981203 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cldn2 |
claudin 2 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN2 protein |
CTD |
PMID:19063874 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Cldn3 |
claudin 3 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN3 protein |
CTD |
PMID:19063874 |
|
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
|
|
G |
Cldn4 |
claudin 4 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN4 protein |
CTD |
PMID:19063874 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
sanguinarine results in decreased expression of CLDN5 protein |
CTD |
PMID:19063874 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression increases activity |
ISO EXP |
sanguinarine results in decreased activity of CYP1A1 protein sanguinarine results in increased expression of CYP1A1 mRNA; sanguinarine results in increased expression of CYP1A1 protein sanguinarine results in increased activity of CYP1A1 protein |
CTD |
PMID:15993743 PMID:24300172 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression increases activity |
ISO |
sanguinarine results in increased expression of CYP1B1 mRNA sanguinarine results in increased activity of CYP1B1 protein |
CTD |
PMID:15993743 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dedd2 |
death effector domain containing 2 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of DEDD2 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression decreases expression |
ISO |
sanguinarine promotes the reaction [Reactive Oxygen Species results in increased activity of EGR1 protein] sanguinarine results in increased expression of EGR1 protein sanguinarine results in decreased expression of EGR1 protein |
CTD |
PMID:23660334 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of FAS mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of FASLG mRNA |
CTD |
PMID:24345465 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases expression |
ISO |
sanguinarine results in increased expression of GGT1 protein |
CTD |
PMID:15981203 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of GSR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of GSR protein |
CTD |
PMID:20691676 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression |
ISO |
sanguinarine inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]; sanguinarine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GSTP1 mRNA]; sanguinarine inhibits the reaction [TNF protein results in increased expression of GSTP1 mRNA] sanguinarine results in increased expression of GSTP1 protein |
CTD |
PMID:15313406 PMID:15981203 PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hal |
histidine ammonia lyase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of HAL protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of HAL protein |
CTD |
PMID:20691676 |
|
NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
decreases activity |
ISO |
sanguinarine results in decreased activity of HPGDS protein |
CTD |
PMID:25603235 |
|
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
|
|
G |
Ltb |
lymphotoxin beta |
increases expression multiple interactions |
ISO |
sanguinarine results in increased expression of LTB mRNA [sanguinarine co-treated with arsenic trioxide] results in increased expression of LTB mRNA |
CTD |
PMID:24345465 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
sanguinarine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19135517 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19135517 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19135517 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases phosphorylation |
ISO |
pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:19135517 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
sanguinarine results in decreased expression of MMP2 mRNA; sanguinarine results in decreased expression of MMP2 protein |
CTD |
PMID:19063874 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
ISO |
sanguinarine results in decreased expression of MMP9 mRNA; sanguinarine results in decreased expression of MMP9 protein |
CTD |
PMID:19063874 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
increases expression |
ISO |
sanguinarine results in increased expression of NFKBIZ mRNA |
CTD |
PMID:24345465 |
|
NCBI chr11:44,782,676...44,810,723
Ensembl chr11:44,782,676...44,810,723
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of NLRP1 mRNA sanguinarine results in increased expression of NLRP1 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression increases reduction multiple interactions |
ISO EXP |
sanguinarine results in decreased expression of NQO1 mRNA; sanguinarine results in decreased expression of NQO1 protein NQO1 protein results in increased reduction of sanguinarine NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in decreased expression of BCL2 protein]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX mRNA]; NQO1 protein inhibits the reaction [sanguinarine results in increased expression of BAX protein] |
CTD |
PMID:22021338 PMID:24300172 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of PMAIP1 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of PYCARD mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression |
ISO |
sanguinarine results in decreased expression of SNAI1 protein |
CTD |
PMID:19063874 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
sanguinarine inhibits the reaction [TNF protein results in increased expression of GSTP1 mRNA] |
CTD |
PMID:15313406 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[sanguinarine co-treated with arsenic trioxide] results in increased expression of TNFRSF1B mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases expression |
ISO |
[sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sanguinarine co-treated with arsenic trioxide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sanguinarine co-treated with arsenic trioxide] results in increased expression of TNFSF10 mRNA; [sanguinarine co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [sanguinarine co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; TNFSF10 protein results in increased susceptibility to [arsenic trioxide co-treated with sanguinarine] sanguinarine results in increased expression of TNFSF10 mRNA |
CTD |
PMID:24345465 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
ISO |
[9,10-Dimethyl-1,2-benzanthracene co-treated with [Tetradecanoylphorbol Acetate co-treated with sanguinarine]] results in decreased activity of TYR protein; [[9,10-Dimethyl-1,2-benzanthracene co-treated with Tetradecanoylphorbol Acetate] co-treated with sanguinarine] results in decreased activity of TYR protein |
CTD |
PMID:20691676 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[sanguinarine results in increased chemical synthesis of Reactive Oxygen Species] which results in decreased expression of XIAP protein |
CTD |
PMID:23660334 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|